Discussion and Concluding Remarks

Slides:



Advertisements
Similar presentations
Depression in adults with a chronic physical health problem
Advertisements

severIIIa Delay cannot be tolerated if delayed ER or admission suspected Complicated cases. Rare cases. Need to know.
The MS Clinic Alastair Lansbury Neurologist. What is MS ? Inflammatory Central Nervous System Autoimmune Relapses and remission (Progressive forms) Any.
An Introduction to Multiple Sclerosis. What is MS? Common symptoms. Diagnosis & potential treatments. Case Studies Support for people with MS and carers.
Multiple Sclerosis Definition: Multiple sclerosis (MS) is a disease of the central nervous system (CNS); it damages the protective coating around the.
Rituximab (RITUXAN) & Multiple Sclerosis
INTERACTIVE QUESTIONS. Discussion Question What is chronic joint pain? Pathophysiology.
INTERACTIVE QUESTIONS. Discussion Question What is central sensitization/ dysfunctional pain? Pathophysiology.
Fingolimod Therapy for Multiple Sclerosis
Multiple Sclerosis Abdulelah Nuqali Intern. DemyelinationCNSAquired Multiple Sclerosis Optic neuritis Acute Disseminated Encephalomyelitis Hereditary.
Spinal Cord Stimulators in Neuropathic Pain. Introduction Chronic pain is very common Immense physical, psychological, societal impact Financial burden.
Multiple Sclerosis (Definition)  “Multiple Sclerosis is a progressive demyelination of neurons in the central nervous system (the Brain and the Spinal.
MULTIPLE SCLEROSIS THE INS AND OUTS. OVERVIEW - An autoimmune disease that attacks the myelin on the nerves within the CNS. The classic symptoms may include.
Recognizing and Treating Multiple Sclerosis in the Primary Care Setting.
Pediatric Neurology Use of Biologic and Chemotherapeutic Agents Pediatric Neurology Use of Biologic and Chemotherapeutic Agents.
Adam Percey. What is it?  MS is a disease of the central nervous system.  What happens is the myelin sheaths around the axon of a nerve fade away. These.
Polymyalgia Rheumatica A micro-teach of BSR & BHPR guidelines
Sagittal FLAIR images - Stable nonenhancing hyperintensities within the pericallosal white matter and bilateral centrum semiovale, consistent with known.
CHAPTER 23: Neurological Disorders in Women. Introduction Gender differences exist in the development and expression of several neurological disorders,
MS مولتیپل اسکلروزیس. Client with Multiple Sclerosis Description Chronic demyelinating disease of CNS associated with - abnormal immune response to environmental.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
EXEMPLAR OF MULTIPLE SCLEROSIS INTRODUCTION AND ASSESSMENT.
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
How To Design a Clinical Trial
Dennis Bourdette, MD VA MS Center of Excellence-West and
Integrated Management of Childhood Illnesses
CATEGORY: IMMUNE DYSFUNCTION Multiple Sclerosis Lindsay Nicholson, University of Bristol, UK [ Multiple sclerosis (MS) is.
Multiple Sclerosis Ian Haslam 486. What is Multiple Sclerosis? An autoimmune disease that attacks the bodies own nerve cells Leads to partial disability.
How To Design a Clinical Trial
Four Known Types of MS Clinically isolated syndrome (CIS)
Multiple Sclerosis (MS)
Multiple Sclerosis [
Applying the New Multiple Sclerosis Guidelines to Clinical Practice
Glaucoma.
COPD by the Guidelines.
Making Decisions With Your Osteoarthritis Patients
Diagnosing Rheumatoid Arthritis Early
Motor Fluctuations in Parkinson Disease: Options and Strategies
Parkinson Disease:.
The Patient Journey to Remission in MDD: A Collaborative Approach
Nat. Rev. Neurol. doi: /nrneurol
What Predicts Disability Progression in Multiple Sclerosis?
New Challenges Facing Multiple Sclerosis Nurses
Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.
The Latest Data on Oral Prostacyclin Therapy in PAH
Before and After: Patient Cases in Onychomycosis
Clinical Cases in Glaucoma Treatment
Patient-Centric Approach to the Management of Spasticity
Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer
Figure 3 Archetypal MS clinical course depicted over 20 years
Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.
Treating to Target in MS
Introduction. Clinical Scenario: Encouraging Adherence in Patients with Schizophrenia.
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Figure 1 Evolution of multiple sclerosis
Management of Systemic Lupus Erythematosus
Atopic Dermatitis in the Pediatric Practice
Pediatric Multiple Sclerosis: The Dawn of a New Era?
The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.
Diagnosing Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome
Managing symptoms in MS – Ernie Butler
CASE STUDIES.
The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis
MS, Age, and Immune Function
Merging the Art and Science of Managing nOH in Clinical Practice
Ask the Psoriasis Expert
Shared Decision Making in MS
The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?
Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis Brian.
Motor Fluctuations in PD
Presentation transcript:

Discussion and Concluding Remarks

ARS Polling How familiar are you now with how MS is diagnosed? Very Somewhat Not at all

ARS Polling How familiar are you now with the revised McDonald criteria in assessing MS patients? Very somewhat Not at all

ARS Polling Very Somewhat Not at all How familiar are you now with the CMSC standardized protocol for performing MRIs? Very Somewhat Not at all

ARS Polling How often do you now plan to order MRIs for patients you suspect have MS? Always Very often Sometimes Not very often Never

ARS Polling How often do you now plan to refer patients for further MS assessment/treatment at the time of a first clinical episode likely to be MS? Always Very often Sometimes Not very often Never

ARS Polling Always Very often Sometimes Not very often Never How often do you now plan to provide patients with strategies for managing common side effects of first-line MS therapies? Always Very often Sometimes Not very often Never

ARS Polling How often do you now plan to ask patients nonjudgmentally about adherence (eg, “How many injections have you missed in the past 2 months?”)? Always Very often Sometimes Not very often Never

ARS Polling How often do you now plan to recommend pharmacologic and nonpharmacologic therapies to manage bothersome MS symptoms (eg, fatigue, bladder dysfunction, spasticity)? Always Very often Sometimes Not very often Never

Final Conclusions Pathogenesis of MS involves interactions between genetic and environmental factors; results in inflammation and axonal loss Diagnosis is based on clinical and radiologic factors High-risk CIS should be treated the same as CDMS MS therapies can reduce relapse rates and disability progression After starting therapy, monitor response, tolerability, and adherence Several new therapies are being developed, some oral There are many treatments for common MS symptoms that can improve QOL—ask patients about their symptoms Various resources are available to help (eg, NMSS, MSAA, Multiple Sclerosis Resource Network–Northwest Region) Consider referral to MS Centers for complicated cases